Clinical Trial Search

Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants

Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio

Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events

Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants

Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio

Primary: Remission of Vasculitis — 95 Percentage of participants

Primary: Death From All Causes — 10; 5 Participants

Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change

Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…

Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants

Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants

Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: Disease Remission — 63; 52 Participants — p=<0.001

Primary: Time to First Relapse — NA; NA Days — p=0.884

Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants

Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072

Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants

Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day

Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESI) — 69; 26; 42 Participants

Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001

Primary: Change in Proteinuria — 4.56; 1.36 ratio

Primary: Percentage of Complete Remission — 4; 3 Participants

Primary: Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9 — -0.9; -1.0 score on a scale — p=0.9670

Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants

Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg

Primary: Number of Participants With Adverse Events — 15; 12 Participants

Primary: Incidence of Chronic GVHD — 5 number participants with chronic GVHD

Primary: Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group. — 2.429 g/dL — p=<0.0001

Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants